(FMTX) – Company Press Releases
-
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease
-
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
-
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
-
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
-
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
-
Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Forma Therapeutics Announces Appointment of New Executive Team Members
-
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
-
Forma Therapeutics to Present at the Jefferies Healthcare Conference
-
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
-
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
-
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
-
Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
-
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
-
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
-
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
-
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
-
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
-
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
-
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
-
Bolt Biotherapeutics Announces Changes to its Board of Directors
-
Bolt Biotherapeutics Announces Changes to its Board of Directors
-
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
-
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
-
Mission BioCapital Announces $275 Million Fund V
-
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
-
Forma Therapeutics to Participate in Upcoming Investor Conferences
-
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
-
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
-
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
-
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
-
Forma Therapeutics to Participate in Upcoming Investor Conferences
-
Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
-
Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
-
Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
-
Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
-
Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
-
Forma Therapeutics to Participate in Upcoming Investor Conferences
-
Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
-
Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors
-
Forma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
-
Forma Therapeutics Announces Pricing of Public Offering
-
Forma Therapeutics Launches Proposed Public Offering
-
Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SC
-
Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Back to FMTX Stock Lookup
